Literature DB >> 17282997

The phenotypic spectrum of rapid-onset dystonia-parkinsonism (RDP) and mutations in the ATP1A3 gene.

Allison Brashear1, William B Dobyns, Patricia de Carvalho Aguiar, Michel Borg, C J M Frijns, Seema Gollamudi, Andrew Green, João Guimaraes, Bret C Haake, Christine Klein, Gurutz Linazasoro, Alexander Münchau, Deborah Raymond, David Riley, Rachel Saunders-Pullman, Marina A J Tijssen, David Webb, Jacek Zaremba, Susan B Bressman, Laurie J Ozelius.   

Abstract

Rapid-onset dystonia-parkinsonism (RDP) (also known as DYT12) is characterized by the abrupt onset of dystonia and parkinsonism and is caused by mutations in the ATP1A3 gene. We obtained clinical data and sequenced the ATP1A3 gene in 49 subjects from 21 families referred with 'possible' RDP, and performed a genotype-phenotype analysis. Of the new families referred for study only 3 of 14 families (21%) demonstrated a mutation in the ATP1A3 gene, but no new mutations were identified beyond our earlier report of 6. Adding these to previously reported families, we found mutations in 36 individuals from 10 families including 4 de novo mutations and excluded mutations in 13 individuals from 11 families. The phenotype in mutation positive patients included abrupt onset of dystonia with features of parkinsonism, a rostrocaudal gradient, and prominent bulbar findings. Other features found in some mutation carriers included common reports of triggers, minimal or no tremor at onset, occasional mild limb dystonia before the primary onset, lack of response to dopaminergic medications, rare abrupt worsening of symptoms later in life, stabilization of symptoms within a month and minimal improvement overall. In comparing ATP1A3 mutation positive and negative patients, we found that tremor at onset of symptoms, a reversed rostrocaudal gradient, and significant limb pain exclude a diagnosis of RDP. A positive family history is not required. Genetic testing for the ATP1A3 gene is recommended when abrupt onset, rostrocaudal gradient and prominent bulbar findings are present.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17282997     DOI: 10.1093/brain/awl340

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  81 in total

Review 1.  Juvenile parkinsonism: epidemiology, diagnosis and treatment.

Authors:  Teri R Thomsen; Robert L Rodnitzky
Journal:  CNS Drugs       Date:  2010-06       Impact factor: 5.749

2.  The rapid-onset dystonia parkinsonism mutation D923N of the Na+, K+-ATPase alpha3 isoform disrupts Na+ interaction at the third Na+ site.

Authors:  Anja Pernille Einholm; Mads S Toustrup-Jensen; Rikke Holm; Jens Peter Andersen; Bente Vilsen
Journal:  J Biol Chem       Date:  2010-06-24       Impact factor: 5.157

3.  New triggers and non-motor findings in a family with rapid-onset dystonia-parkinsonism.

Authors:  Richard L Barbano; Deborah F Hill; Beverly M Snively; Laney S Light; Niki Boggs; W Vaughn McCall; Mark Stacy; Laurie Ozelius; Kathleen J Sweadner; Allison Brashear
Journal:  Parkinsonism Relat Disord       Date:  2012-04-24       Impact factor: 4.891

Review 4.  Engineering animal models of dystonia.

Authors:  Janneth Oleas; Fumiaki Yokoi; Mark P DeAndrade; Antonio Pisani; Yuqing Li
Journal:  Mov Disord       Date:  2013-06-15       Impact factor: 10.338

5.  Revising rapid-onset dystonia-parkinsonism: Broadening indications for ATP1A3 testing.

Authors:  Ihtsham U Haq; Beverly M Snively; Kathleen J Sweadner; Cynthia K Suerken; Jared F Cook; Laurie J Ozelius; Charlotte Miller; William V McCall; Christopher T Whitlow; Allison Brashear
Journal:  Mov Disord       Date:  2019-07-30       Impact factor: 10.338

6.  Rapid-onset dystonia-parkinsonism in a child with a novel atp1a3 gene mutation.

Authors:  I A Anselm; K J Sweadner; S Gollamudi; L J Ozelius; B T Darras
Journal:  Neurology       Date:  2009-08-04       Impact factor: 9.910

7.  Rapid-onset dystonia-parkinsonism: case report.

Authors:  Marina Svetel; Laurie J Ozelius; Amber Buckley; Katja Lohmann; Lela Brajković; Christine Klein; Vladimir S Kostić
Journal:  J Neurol       Date:  2010-03       Impact factor: 4.849

8.  A Transgenic Mouse Model to Selectively Identify α3 Na,K-ATPase Expressing Cells in the Nervous System.

Authors:  Maxim Dobretsov; Abdallah Hayar; Neriman T Kockara; Maxim Kozhemyakin; Kim E Light; Pankaj Patyal; Dwight R Pierce; Patricia A Wight
Journal:  Neuroscience       Date:  2018-07-19       Impact factor: 3.590

Review 9.  What's new in dystonia?

Authors:  Vicki Shanker; Susan B Bressman
Journal:  Curr Neurol Neurosci Rep       Date:  2009-07       Impact factor: 5.081

10.  A new tyrosine hydroxylase genotype with orofacial dyskinaesia.

Authors:  Ahood M Al-Muslamani; Fouad Ali; Fatima Mahmood
Journal:  Sultan Qaboos Univ Med J       Date:  2014-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.